Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Article
PubMed
Google Scholar
Matsuda K, Tamura K, Iwamoto H, et al. Tumor sidedness is associated with survival in patients with synchronous colorectal peritoneal carcinomatosis. Oncology. 2020;98(4):230–6.
Article
PubMed
Google Scholar
Zhang RX, Ma WJ, Gu YT, et al. Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis. World J Surg Oncol. 2017;15(1):138.
Article
PubMed
PubMed Central
Google Scholar
Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26(5):1358–65.
Article
PubMed
Google Scholar
Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211–9.
Article
PubMed
Google Scholar
Ha GW, Kim JH, Lee MR. Oncologic effects of primary tumor-sidedness on patients with stages 1-3 colon cancer: a Meta-analysis. Ann Surg Oncol. 2019;26(5):1366–75.
Article
PubMed
Google Scholar
Karim S, Brennan K, Nanji S, et al. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol. 2017;3(10):1386–92.
Article
PubMed
PubMed Central
Google Scholar
Warschkow R, Sulz MC, Marti L, et al. Better survival in right-sided versus left-sided stage I - III colon cancer patients. BMC Cancer. 2016;16:554.
Article
PubMed
PubMed Central
Google Scholar
Ishihara S, Murono K, Sasaki K, et al. Impact of primary tumor location on postoperative recurrence and subsequent prognosis in nonmetastatic Colon cancers: a multicenter retrospective study using a propensity score analysis. Ann Surg. 2018;267(5):917–21.
Article
PubMed
Google Scholar
Malakorn S, Ouchi A, Hu CY, et al. Tumor sidedness, recurrence, and survival after curative resection of localized colon cancer. Clin Colorectal Cancer. 2021;20(1):e53–60.
Article
PubMed
Google Scholar
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.
Article
PubMed
Google Scholar
Messersmith WA. NCCN guidelines updates: Management of Metastatic Colorectal Cancer. J Natl Compr Cancer Netw. 2019;17(5.5):599–601.
Google Scholar
Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
Article
PubMed
Google Scholar
Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.
Article
PubMed
Google Scholar
Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705.
Article
CAS
PubMed
Google Scholar
Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7.
Article
CAS
PubMed
Google Scholar
Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.
Article
CAS
PubMed
Google Scholar
Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17(10):1426–34.
Article
CAS
PubMed
Google Scholar
CALGB/SWOG. C80405: a phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. Clin Adv Hematol Oncol. 2006;4(6):452–3.
Google Scholar
Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706–13.
Article
CAS
PubMed
Google Scholar
Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012;55(2):128–33.
Article
PubMed
Google Scholar
Liu J, Wang B, Fang W. Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer. Eur J Hosp Pharm. 2020;27(5):267–70.
Article
PubMed
PubMed Central
Google Scholar
Haupt S, Caramia F, Herschtal A, et al. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nat Commun. 2019;10(1):5385.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kaiser AM, Kang JC, Chan LS, et al. The prognostic impact of the time interval to recurrence for the mortality in recurrent colorectal cancer. Color Dis. 2006;8(8):696–703.
Article
CAS
Google Scholar
Westberg K, Palmer G, Johansson H, et al. Time to local recurrence as a prognostic factor in patients with rectal cancer. Eur J Surg Oncol. 2015;41(5):659–66.
Article
CAS
PubMed
Google Scholar
Li H, Jin X, Liu P, et al. Time to local recurrence as a predictor of survival in unrecetable gastric cancer patients after radical gastrectomy. Oncotarget. 2017;8(51):89203–13.
Article
PubMed
PubMed Central
Google Scholar
Shida D, Inoue M, Tanabe T, et al. Prognostic impact of primary tumor location in stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study. J Gastroenterol. 2020;55(10):958–68.
Article
CAS
PubMed
Google Scholar
Lee JM, Han YD, Cho MS, et al. Impact of tumor sidedness on survival and recurrence patterns in colon cancer patients. Ann Surg Treat Res. 2019;96(6):296–304.
Article
PubMed
PubMed Central
Google Scholar
Sparreboom CL, van Groningen JT, Lingsma HF, et al. Different risk factors for early and late colorectal anastomotic leakage in a Nationwide audit. Dis Colon Rectum. 2018;61(11):1258–66.
Article
PubMed
Google Scholar
Riihimäki M, Hemminki A, Sundquist J, et al. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.
Article
PubMed
PubMed Central
CAS
Google Scholar
Meltzer S, Bakke KM, Rød KL, et al. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors? Clin Transl Radiat Oncol. 2020;21:5–10.
Article
PubMed
Google Scholar
Gao Z, Guo B, Gao R, et al. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20.
PubMed
PubMed Central
Google Scholar
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes Chemoresistance to colorectal Cancer by modulating autophagy. Cell. 2017;170(3):548–563.e16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Missiaglia E, Jacobs B, D'Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001.
Article
CAS
PubMed
Google Scholar
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–6.
Article
PubMed
Google Scholar
Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466–74.
Article
CAS
PubMed
Google Scholar
Loree JM, Pereira AAL, Lam M, et al. Classifying colorectal Cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24(5):1062–72.
Article
CAS
PubMed
Google Scholar
Benhattar J, Cerottini JP, Saraga E, et al. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer. 1996;69(3):190–2.
Article
CAS
PubMed
Google Scholar
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38.
Article
CAS
PubMed
Google Scholar
Radkiewicz C, Johansson ALV, Dickman PW, et al. Sex differences in cancer risk and survival: a Swedish cohort study. Eur J Cancer. 2017;84:130–40.
Article
PubMed
Google Scholar
Sloan JA, Loprinzi CL, Novotny PJ, et al. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol. 2000;18(2):412–20.
Article
CAS
PubMed
Google Scholar
Nozawa H, Kawai K, Sasaki K, et al. Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer. Int J Clin Pract. 2021;75(11):e14863.
Yamada Y, Koizumi W, Nishikawa K, et al. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Cancer Sci. 2019;110(9):2875–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Athauda A, Nankivell M, Langley RE, et al. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: a pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). Eur J Cancer. 2020;137:45–56.
Article
CAS
PubMed
Google Scholar
Singh S, Parulekar W, Murray N, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850–6.
Article
PubMed
Google Scholar
Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin study group. J Clin Oncol. 2005;23(31):8003–11.
Article
CAS
PubMed
Google Scholar
Japanese Society for Cancer of the Colon and Rectum. JSCCR guidelines 2005 for the treatment of colorectal Cancer. Tokyo: Kanehara & CO. LTD.; 2005.
Google Scholar